Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MicroRNA 609 (miR-609) is a small, non-coding RNA (20–24 nucleotides) classified within the microRNA family. It is transcribed as a primary transcript that undergoes cleavage to form a stem-loop precursor and then a mature miRNA, which is incorporated into the RNA-induced silencing complex (RISC)[1]. miR-609 guides RISC to target mRNAs by imperfect base-pairing, most commonly resulting in translational inhibition or destabilization of the mRNA, thereby regulating gene expression post-transcriptionally[1][3][5]. Like other microRNAs, miR-609 likely participates in regulatory networks that modulate cellular processes such as proliferation, differentiation, apoptosis, and may contribute to disease mechanisms, though no highly specific disease or drug/target interaction data is available for this miRNA[1][2][3][4][5].
Translational inhibition of target mRNAs; mRNA destabilization and decay; mRNA cleavage (when pairing is perfect or near-perfect)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MicroRNA 609 (miR-609).